$1.43 Billion is the total value of SPHERA FUNDS MANAGEMENT LTD.'s 134 reported holdings in Q2 2021. The portfolio turnover from Q1 2021 to Q2 2021 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| XBI | New | SPDR SER TRput | $84,625,000 | – | 625,000 | +100.0% | 5.72% | – |
| MRK | New | MERCK & CO INCput | $60,085,000 | – | 772,600 | +100.0% | 4.06% | – |
| XENE | New | XENON PHARMACEUTICALS INC | $51,412,000 | – | 276,130 | +100.0% | 3.48% | – |
| XLK | New | SELECT SECTOR SPDR TRput | $31,009,000 | – | 210,000 | +100.0% | 2.10% | – |
| TAN | New | INVESCO EXCH TRADED FD TR IIcall | $18,759,000 | – | 210,000 | +100.0% | 1.27% | – |
| BIIB | New | BIOGEN INCcall | $17,313,000 | – | 50,000 | +100.0% | 1.17% | – |
| HOWL | New | WEREWOLF THERAPEUTICS INC | $12,049,000 | – | 706,294 | +100.0% | 0.82% | – |
| TWLO | New | TWILIO INCcl a | $10,445,000 | – | 26,500 | +100.0% | 0.71% | – |
| IOVA | New | IOVANCE BIOTHERAPEUTICS INC | $9,852,000 | – | 378,642 | +100.0% | 0.67% | – |
| FB | New | FACEBOOK INCcl a | $9,388,000 | – | 27,000 | +100.0% | 0.64% | – |
| SEDG | New | SOLAREDGE TECHNOLOGIES INC | $8,899,000 | – | 32,200 | +100.0% | 0.60% | – |
| NTLA | New | INTELLIA THERAPEUTICS INC | $8,508,000 | – | 52,550 | +100.0% | 0.58% | – |
| NAUT | New | NAUTILUS BIOTECHNOLOGY INC | $8,080,000 | – | 800,000 | +100.0% | 0.55% | – |
| IONS | New | IONIS PHARMACEUTICALS INCcall | $7,443,000 | – | 186,600 | +100.0% | 0.50% | – |
| VRNT | New | VERINT SYS INC | $6,761,000 | – | 150,000 | +100.0% | 0.46% | – |
| ALT | New | ALTIMMUNE INC | $6,731,000 | – | 683,395 | +100.0% | 0.46% | – |
| AGIO | New | AGIOS PHARMACEUTICALS INCcall | $6,393,000 | – | 116,000 | +100.0% | 0.43% | – |
| ATER | New | ATERIAN INC | $5,852,000 | – | 399,999 | +100.0% | 0.40% | – |
| QURE | New | UNIQURE NV | $5,298,000 | – | 172,000 | +100.0% | 0.36% | – |
| FVRR | New | FIVERR INTL LTD | $5,214,000 | – | 21,500 | +100.0% | 0.35% | – |
| ATER | New | ATERIAN INCcall | $5,202,000 | – | 355,600 | +100.0% | 0.35% | – |
| CVRX | New | CVRX INC | $4,200,000 | – | 150,000 | +100.0% | 0.28% | – |
| RUN | New | SUNRUN INC | $4,016,000 | – | 72,000 | +100.0% | 0.27% | – |
| BEAM | New | BEAM THERAPEUTICS INC | $3,659,000 | – | 28,425 | +100.0% | 0.25% | – |
| PLTK | New | PLAYTIKA HLDG CORP | $3,576,000 | – | 150,000 | +100.0% | 0.24% | – |
| ANNX | New | ANNEXON INC | $3,339,000 | – | 148,318 | +100.0% | 0.23% | – |
| ISEE | New | IVERIC BIO INC | $3,155,000 | – | 500,000 | +100.0% | 0.21% | – |
| TRMR | New | TREMOR INTL LTDads | $2,985,000 | – | 150,000 | +100.0% | 0.20% | – |
| S | New | SENTINELONE INCcl a | $2,907,000 | – | 68,400 | +100.0% | 0.20% | – |
| FREQ | New | FREQUENCY THERAPEUTICS INC | $2,741,000 | – | 275,160 | +100.0% | 0.18% | – |
| CYT | New | CYTEIR THERAPEUTICS INC | $2,675,000 | – | 125,000 | +100.0% | 0.18% | – |
| PRGO | New | PERRIGO CO PLC | $2,407,000 | – | 52,500 | +100.0% | 0.16% | – |
| TWST | New | TWIST BIOSCIENCE CORP | $2,399,000 | – | 18,000 | +100.0% | 0.16% | – |
| IPSC | New | CENTURY THERAPEUTICS INC | $2,347,000 | – | 80,000 | +100.0% | 0.16% | – |
| GLUE | New | MONTE ROSA THERAPEUTICS INC | $2,270,000 | – | 100,000 | +100.0% | 0.15% | – |
| ALDX | New | ALDEYRA THERAPEUTICS INC | $1,700,000 | – | 150,000 | +100.0% | 0.12% | – |
| PLRX | New | PLIANT THERAPEUTICS INC | $1,485,000 | – | 51,000 | +100.0% | 0.10% | – |
| OMIC | New | SINGULAR GENOMICS SYSTEMS IN | $1,480,000 | – | 53,867 | +100.0% | 0.10% | – |
| PRAX | New | PRAXIS PRECISION MEDICINES I | $1,382,000 | – | 75,600 | +100.0% | 0.09% | – |
| CELC | New | CELCUITY INC | $1,080,000 | – | 45,000 | +100.0% | 0.07% | – |
| CMLTU | New | CM LIFE SCIENCES III INCunit 04/30/2028 | $821,000 | – | 75,000 | +100.0% | 0.06% | – |
| GRPH | New | GRAPHITE BIO INC | $767,000 | – | 24,957 | +100.0% | 0.05% | – |
| ELEV | New | ELEVATION ONCOLOGY INC | $407,000 | – | 30,000 | +100.0% | 0.03% | – |
| MGIC | New | MAGIC SOFTWARE ENTERPRISES Lord | $259,000 | – | 15,976 | +100.0% | 0.02% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
- Sphera Global Healthcare GP Ltd #1
- Sphera Global Healthcare Management LP #2
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-08-17
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| TEVA PHARMACEUTICAL-SP ADR | 36 | Q3 2023 | 8.4% |
| MERCK & CO INC NEW | 35 | Q3 2023 | 8.4% |
| NICE Systems Ltd | 27 | Q3 2023 | 4.4% |
| BIOGEN INC | 26 | Q3 2023 | 6.7% |
| AMICUS THERAPEUTICS INC | 26 | Q2 2022 | 4.3% |
| PFIZER INC | 25 | Q3 2023 | 9.2% |
| SAREPTA THERAPEUTICS INC | 25 | Q3 2023 | 3.2% |
| JOHNSON & JOHNSON | 24 | Q3 2023 | 8.0% |
| UNIQURE NV | 23 | Q3 2023 | 1.2% |
| SYNDAX PHARMACEUTICALS INC | 22 | Q3 2023 | 3.9% |
View SPHERA FUNDS MANAGEMENT LTD.'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Cyclacel Pharmaceuticals, Inc. | February 06, 2023 | 250,000 | 2.0% |
| Altimmune, Inc. | February 14, 2022 | 1,244,241 | 3.1% |
| Allot Ltd. | February 16, 2021 | 1,129,054 | 3.2% |
| Larimar Therapeutics, Inc. | February 16, 2021 | ? | ? |
| Neos Therapeutics, Inc. | February 16, 2021 | ? | ? |
| Orgenesis Inc. | February 16, 2021 | 525,216 | 0.0% |
| Sio Gene Therapies Inc. | February 16, 2021 | ? | ? |
| X4 Pharmaceuticals, Inc | February 16, 2021 | 250,000 | 0.0% |
| Axovant Gene Therapies Ltd. | February 25, 2020 | 2,931,017 | 8.0% |
| Axovant Gene Therapies Ltd. | February 11, 2020 | 398,540 | 1.8% |
View SPHERA FUNDS MANAGEMENT LTD.'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR/A | 2024-02-15 |
| 13F-HR | 2024-02-14 |
| SC 13G | 2024-02-08 |
| SC 13G/A | 2024-02-05 |
| SC 13G/A | 2024-02-05 |
| SC 13G/A | 2024-02-05 |
| SC 13G/A | 2024-02-05 |
| 13F-HR | 2023-11-14 |
| SC 13G | 2023-10-10 |
| SC 13G | 2023-08-30 |
View SPHERA FUNDS MANAGEMENT LTD.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.